# RNN 1st Gen Model Mallinckrodt plc Pharmaceutical preparations

Stock predictor AI models:
Subscribe >> Deal exit on
May 3, 2018
Deal entry on
May 3, 2018
0.87%Expected margin
78.85% successful of 52 deals
$ 0.75 Last close price
at 09-oct-2020


Model's trade recommendations 4.22% Return for period

-3.33% Annual return

$1.12B Market Cap

β 1.13  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period 4.22%
52wk return -18.83%
52wk Range
Sortino ratio 0.06
Sharpe ratio 0.05
Norm. RMSE 1.22%
Downside risk 26.92%
Volatility 0.00%
  • BUY Analysts consensus recommendation

Mallinckrodt Plc. is engaged in pharmaceuticals business. It develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company's Specialty Pharmaceuticals segment includes branded and generic drugs and Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt Plc. is based in Dublin, Ireland.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Mallinckrodt plc (MNK) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 22, 2015.

Market data for MNK model training are being downloaded from the Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are accounted for in this model in the form of the historical data coincided with outbreaks and other global events in the past used to train ML prediction model for MNK.

Model is being retrained on a daily basis.

Float 85M
P/E 1.73
Shares Outstanding 86M
% Held by Insiders 1.80%
% Held by Institutions NaN%
EPS (last reported FY) $7.49
EPS (last reported Q) $2.01
EPS, estimated (last reported Q) $1.72
Total revenues $3 B
Net income $2 B